Study on Pembrolizumab and Targeted Radiation Therapy for Early Stage Relapsed or Hard-to-Treat Hodgkin Lymphoma

Inclusion Criteria

• Patients with early stage Hodgkin lymphoma (stage I-II) who were treated with chemotherapy alone and have relapsed with early stage disease.
• Patients with early stage Hodgkin lymphoma (stage I-II) who were treated with chemotherapy alone and have primary refractory disease (disease still present after initial treatment) without severe symptoms and with each affected area smaller than 10 cm.
• Patients with early stage Hodgkin lymphoma (stage I-II) who were treated with both chemotherapy and radiation and have relapsed with early stage disease outside the previous radiation area.
• Must have a confirmed diagnosis of classical Hodgkin Lymphoma after imaging shows relapsed or refractory disease.
• Age 12 or older.
• Good overall health with a performance status score of 0-1 or a Lansky score of 50 or higher for ages 12-15.
• Adequate organ function based on specific blood tests done within 14 days before starting treatment.
• Women of childbearing potential must have a negative pregnancy test before starting treatment and agree to use two methods of birth control or be surgically sterile during the study and for 120 days after the last dose.
• Men must agree to use effective contraception during the study and for 120 days after the last dose.

Exclusion Criteria

• Patients with advanced stage (III or IV) Hodgkin lymphoma at diagnosis or relapse.
• Patients with large tumors (greater than 10 cm) at diagnosis or relapse.
• Patients with active severe symptoms related to Hodgkin lymphoma.
• Patients who have received more than one line of therapy for Hodgkin lymphoma.
• Patients with relapsed or refractory disease within a previous radiation area.
• Patients who have had chemotherapy, targeted therapy, or radiation within 2 weeks before starting the study and have not recovered from side effects.
• Patients with immune system suppression or on systemic steroid therapy within 7 days before starting the study.
• Patients with another progressing cancer requiring treatment, except for certain skin cancers or cervical cancer treated with curative intent.
• Patients with active autoimmune disease requiring treatment in the past 2 years.
• Patients with a history of lung inflammation requiring steroids or active lung disease.
• Patients with active infections requiring intravenous treatment.
• Patients with known HIV, Hepatitis B, or Hepatitis C infections.
• Patients who have received a live vaccine within 30 days before starting the study.
• Patients with any medical condition or lab result that makes them unsuitable for the study.
• Patients who have had a monoclonal antibody treatment within 4 weeks before starting the study and have not recovered from side effects.
• Patients who have had treatment with antibodies targeting PD-1, PD-L1, PD-L2, or CTLA-4.
• Patients with heart or lung function below specific levels before treatment.
• Patients who are pregnant, breastfeeding, or planning to conceive or father children during the study and for 120 days after the last dose.